サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1459809

RSV（RSウイルス）治療薬市場：世界の産業分析、規模、シェア、成長、動向、予測、2023-2031年

Respiratory Syncytial Virus Therapeutics Market (Drug Type: Palivizumab, Ribavirin, and Others; and Dosage Form: Oral, Injectable, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

出版日
ページ情報
英文 176 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.91円
RSV（RSウイルス）治療薬市場：世界の産業分析、規模、シェア、成長、動向、予測、2023-2031年
出版日: 2024年02月01日
発行: Transparency Market Research
ページ情報: 英文 176 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

RSV（RSウイルス）治療薬市場- 調査範囲

TMR社の調査レポート「RSV治療薬の世界市場」は、2023年から2031年までの予測期間における市場の指標に関する貴重な洞察を得るため、過去だけでなく現在の成長動向と機会についても調査しています。2023年を基準年、2031年を予測年として、2017年から2031年までの世界のRSV治療薬市場の収益と予測を提供します。また、2023年から2031年までの世界のRSV治療薬市場の複合年間成長率（CAGR %）も掲載しています。

本レポートは広範な調査を経て作成されました。1次調査では、アナリストが主要オピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。2次調査では、RSV治療薬市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、関連文書を参照しました。

市場スナップショット
2022年の市場価値 11億米ドル
2031年の市場価値 38億米ドル
CAGR 14.6%

当レポートでは、世界のRSV治療薬市場の競合情勢について調査しています。世界のRSV治療薬市場で事業を展開する主要企業が特定され、これらの各企業が様々な属性でプロファイリングされています。企業概要、財務状況、最近の動向、SWOTは、このレポートでプロファイリングされた世界のRSV治療薬市場のプレイヤーの属性です。

目次

第1章 序文

第2章 前提条件と調査手法

第3章 エグゼクティブサマリー：世界市場

第4章 市場概要

  • イントロダクション
  • 市場概要
  • 市場力学
  • 世界市場分析と予測、2017-2031年

第5章 主要洞察

  • パイプライン分析
  • 主要製品/ブランド分析
  • 主要M&A
  • COVID-19パンデミックの産業への影響

第6章 世界市場分析と予測：薬剤タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：薬剤タイプ別、2017年～2031年
    • パリビズマブ
    • リバビリン
    • その他
  • 市場魅力度分析：薬剤タイプ別

第7章 世界市場分析と予測：剤形別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：剤形別、2017年～2031年
    • 経口
    • 注射
    • その他
  • 市場魅力度分析：剤形別

第8章 世界市場分析と予測：流通チャネル別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額予測：流通チャネル別、2017年～2031年
    • ドラッグストア・小売薬局
    • 病院薬局
    • その他
  • 市場魅力度分析：流通チャネル別

第9章 世界市場分析と予測：地域別

  • 主な調査結果
  • 市場金額予測：地域別、2017年～2031年
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力度分析：地域別

第10章 北米市場分析と予測

第11章 欧州市場分析と予測

第12章 アジア太平洋市場分析と予測

第13章 ラテンアメリカ市場分析と予測

第14章 中東・アフリカ市場分析と予測

第15章 競合情勢

  • 市場競合マトリックス（ティア別、企業規模別）
  • 市場シェア分析：企業別（2022年）
  • 企業プロファイル
    • F. Hoffmann-La Roche Ltd.
    • AstraZeneca plc
    • Merck & Co., Inc.
    • AbbVie, Inc.
    • Valeant Pharmaceuticals International, Inc.
    • GlaxoSmithKline plc
    • ReViral Ltd.
    • Gilead Sciences, Inc.
    • Medivir AB
    • Teva Pharmaceuticals Industries Ltd.
図表

List of Tables

  • Table 01: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 02: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017-2031
  • Table 03: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 04: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 07: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017-2031
  • Table 08: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 09: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 11: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017-2031
  • Table 12: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 13: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 15: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017-2031
  • Table 16: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 17: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 19: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017-2031
  • Table 20: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031
  • Table 21: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Drug Type, 2017-2031
  • Table 23: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Dosage Form, 2017-2031
  • Table 24: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2031

List of Figures

  • Figure 01: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) and Distribution (%), by Region, 2022-2031
  • Figure 02: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (US$ Mn), by Drug Type, 2022
  • Figure 03: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Drug Type, 2022
  • Figure 04: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (US$ Mn), by Dosage Form, 2022
  • Figure 05: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Dosage Form, 2022
  • Figure 06: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Revenue (US$ Mn), by Distribution Channel, 2022
  • Figure 07: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Distribution Channel, 2022
  • Figure 08: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share, by Region, 2022
  • Figure 09: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 10: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022-2031
  • Figure 11: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 12: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022-2031
  • Figure 13: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023-2031
  • Figure 14: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
  • Figure 15: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 16: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Region, 2022-2031
  • Figure 17: Global Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 18: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 19: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 20: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Country, 2022-2031
  • Figure 21: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022-2031
  • Figure 22: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022-2031
  • Figure 23: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
  • Figure 24: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 25: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023-2031
  • Figure 26: North America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 27: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 28: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 30: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022-2031
  • Figure 31: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022-2031
  • Figure 32: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
  • Figure 33: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 34: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023-2031
  • Figure 35: Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 36: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 37: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 39: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022-2031
  • Figure 40: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022-2031
  • Figure 41: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
  • Figure 42: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 43: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023-2031
  • Figure 44: Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 45: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 46: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 47: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 48: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022-2031
  • Figure 49: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022-2031
  • Figure 50: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
  • Figure 51: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 52: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023-2031
  • Figure 53: Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 54: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
  • Figure 55: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Country/Sub-region, 2022-2031
  • Figure 57: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Drug Type, 2022-2031
  • Figure 58: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Dosage Form, 2022-2031
  • Figure 59: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Value Share Analysis, by Distribution Channel, 2022-2031
  • Figure 60: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Drug Type, 2023-2031
  • Figure 61: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Dosage Form, 2023-2031
  • Figure 62: Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2023-2031
目次
Product Code: TMRGL42701

Respiratory Syncytial Virus Therapeutics Market - Scope of Report

TMR's report on the global respiratory syncytial virus therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global respiratory syncytial virus therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global respiratory syncytial virus therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the respiratory syncytial virus therapeutics market.

Market Snapshot
Market Value in 2022US$ 1.1 Bn
Market Value in 2031US$ 3.8 Bn
CAGR14.6%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global respiratory syncytial virus therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global respiratory syncytial virus therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global respiratory syncytial virus therapeutics market.

The report delves into the competitive landscape of the global respiratory syncytial virus therapeutics market. Key players operating in the global respiratory syncytial virus therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global respiratory syncytial virus therapeutics market profiled in this report.

Key Questions Answered in Global respiratory syncytial virus therapeutics Market Report:

  • What is the sales/revenue generated by respiratory syncytial virus therapeutics across all regions during the forecast period?
  • What are the opportunities in the global respiratory syncytial virus therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Respiratory Syncytial Virus Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global respiratory syncytial virus therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global respiratory syncytial virus therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global respiratory syncytial virus therapeutics market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Respiratory Syncytial Virus (RSV) Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution/Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, 2017-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Drug Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Drug Type, 2017-2031
    • 6.3.1. Palivizumab
    • 6.3.2. Ribavirin
    • 6.3.3. Others
  • 6.4. Market Attractiveness Analysis, by Drug Type

7. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Dosage Form

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Dosage Form, 2017-2031
    • 7.3.1. Oral
    • 7.3.2. Injectable
    • 7.3.3. Others
  • 7.4. Market Attractiveness Analysis, by Dosage Form

8. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Distribution Channel

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Distribution Channel, 2017-2031
    • 8.3.1. Drug Stores and Retail Pharmacies
    • 8.3.2. Hospital Pharmacies
    • 8.3.3. Others
  • 8.4. Market Attractiveness Analysis, by Dosage Form

9. Global Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region, 2017-2031
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast

  • 10.1. Introduction
  • 10.2. Key Findings
  • 10.3. Market Value Forecast, by Drug Type, 2017-2031
    • 10.3.1. Palivizumab
    • 10.3.2. Ribavirin
    • 10.3.3. Others
  • 10.4. Market Value Forecast, by Dosage Form, 2017-2031
    • 10.4.1. Oral
    • 10.4.2. Injectable
    • 10.4.3. Others
  • 10.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 10.5.1. Drug Stores and Retail Pharmacies
    • 10.5.2. Hospital Pharmacies
    • 10.5.3. Others
  • 10.6. Market Value Forecast, by Country, 2017-2031
    • 10.6.1. U.S.
    • 10.6.2. Canada
  • 10.7. Market Attractiveness Analysis
    • 10.7.1. By Drug Type
    • 10.7.2. By Dosage Form
    • 10.7.3. By Distribution Channel
    • 10.7.4. By Country

11. Europe Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast

  • 11.1. Introduction
  • 11.2. Key Findings
  • 11.3. Market Value Forecast, by Drug Type, 2017-2031
    • 11.3.1. Palivizumab
    • 11.3.2. Ribavirin
    • 11.3.3. Others
  • 11.4. Market Value Forecast, by Dosage Form, 2017-2031
    • 11.4.1. Oral
    • 11.4.2. Injectable
    • 11.4.3. Others
  • 11.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 11.5.1. Drug Stores and Retail Pharmacies
    • 11.5.2. Hospital Pharmacies
    • 11.5.3. Others
  • 11.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.6.1. Germany
    • 11.6.2. U.K.
    • 11.6.3. France
    • 11.6.4. Italy
    • 11.6.5. Spain
    • 11.6.6. Rest of Europe
  • 11.7. Market Attractiveness Analysis
    • 11.7.1. By Drug Type
    • 11.7.2. By Dosage Form
    • 11.7.3. By Distribution Channel
    • 11.7.4. By Country/Sub-region

12. Asia Pacific Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast

  • 12.1. Introduction
  • 12.2. Key Findings
  • 12.3. Market Value Forecast, by Drug Type, 2017-2031
    • 12.3.1. Palivizumab
    • 12.3.2. Ribavirin
    • 12.3.3. Others
  • 12.4. Market Value Forecast, by Dosage Form, 2017-2031
    • 12.4.1. Oral
    • 12.4.2. Injectable
    • 12.4.3. Others
  • 12.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 12.5.1. Drug Stores and Retail Pharmacies
    • 12.5.2. Hospital Pharmacies
    • 12.5.3. Others
  • 12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.6.1. China
    • 12.6.2. Japan
    • 12.6.3. India
    • 12.6.4. Australia & New Zealand
    • 12.6.5. Rest of Asia Pacific
  • 12.7. Market Attractiveness Analysis
    • 12.7.1. By Drug Type
    • 12.7.2. By Dosage Form
    • 12.7.3. By Distribution Channel
    • 12.7.4. By Country/Sub-region

13. Latin America Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast

  • 13.1. Introduction
  • 13.2. Key Findings
  • 13.3. Market Value Forecast, by Drug Type, 2017-2031
    • 13.3.1. Palivizumab
    • 13.3.2. Ribavirin
    • 13.3.3. Others
  • 13.4. Market Value Forecast, by Dosage Form, 2017-2031
    • 13.4.1. Oral
    • 13.4.2. Injectable
    • 13.4.3. Others
  • 13.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 13.5.1. Drug Stores and Retail Pharmacies
    • 13.5.2. Hospital Pharmacies
    • 13.5.3. Others
  • 13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.6.1. Brazil
    • 13.6.2. Mexico
    • 13.6.3. Rest of Latin America
  • 13.7. Market Attractiveness Analysis
    • 13.7.1. By Drug Type
    • 13.7.2. By Dosage Form
    • 13.7.3. By Distribution Channel
    • 13.7.4. By Country/Sub-region

14. Middle East & Africa Respiratory Syncytial Virus (RSV) Therapeutics Market Analysis and Forecast

  • 14.1. Introduction
  • 14.2. Key Findings
  • 14.3. Market Value Forecast, by Drug Type, 2017-2031
    • 14.3.1. Palivizumab
    • 14.3.2. Ribavirin
    • 14.3.3. Others
  • 14.4. Market Value Forecast, by Dosage Form, 2017-2031
    • 14.4.1. Oral
    • 14.4.2. Injectable
    • 14.4.3. Others
  • 14.5. Market Value Forecast, by Distribution Channel, 2017-2031
    • 14.5.1. Drug Stores and Retail Pharmacies
    • 14.5.2. Hospital Pharmacies
    • 14.5.3. Others
  • 14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.6.1. GCC Countries
    • 14.6.2. South Africa
    • 14.6.3. Rest of Middle East & Africa
  • 14.7. Market Attractiveness Analysis
    • 14.7.1. By Drug Type
    • 14.7.2. By Dosage Form
    • 14.7.3. By Distribution Channel
    • 14.7.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
  • 15.2. Market Share Analysis, by Company (2022)
  • 15.3. Company Profiles
    • 15.3.1. F. Hoffmann-La Roche Ltd.
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. AstraZeneca plc
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Merck & Co., Inc.
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. AbbVie, Inc.
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. Valeant Pharmaceuticals International, Inc.
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. GlaxoSmithKline plc
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. ReViral Ltd.
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. Gilead Sciences, Inc.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. Medivir AB
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Teva Pharmaceuticals Industries Ltd.
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview